Eczema Therapeutics Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Canada, Germany, UK, China - Size and Forecast 2024-2028

Eczema Therapeutics Market Forecast 2024-2028

The Global Eczema Therapeutics Market size is forecast to increase by USD 5.81 billion, at a CAGR of 10.28% between 2023 and 2028.

There has been an increasing number of product launches for treating eczema across the globe. Several new product launches introduce additional treatment options for eczema, offering healthcare providers, and patients with a broader range of therapeutic choices. In addition, this expanded treatment landscape enhances the ability to tailor therapy to individual patient needs and preferences, ultimately driving market growth.  Moreover, companies in the global market are focusing on increasing their customer base by providing a comprehensive variety of new and advanced eczema therapeutics. Hence, such factors are positively impacting the market.

What will be the Size of the Market During the Forecast Period?

To learn more about this report, Download Report Sample

Segmentation by Application, Distribution Channel, and Geography Analysis

Eczema is a chronic skin disorder characterized by dermatitis, resulting in rashes, skin redness, and itchy skin. It is often referred to as atopic dermatitis and can lead to dry, cracked, and itchy skin due to disruptions in the skin barrier function. The condition is influenced by genetics and involves an abnormal immune system function. Managing eczema involves various treatments aimed at relieving symptoms such as inflammation and skin itching. Common therapies include steroid creams, ointments, and topical steroids, which target the underlying immune system responses contributing to the disease. Triggers like inhalant and food allergens can exacerbate eczema symptoms, necessitating the use of antihistamines to mitigate allergic reactions. Understanding the role of genetics in eczema susceptibility aids in developing personalized treatment plans tailored to individual patients' needs. In the market, ongoing research focuses on improving skin barrier integrity and addressing immune system dysregulation to provide effective and long-lasting relief for eczema patients.

Application Analysis

The atopic dermatitis segment is estimated to witness significant growth during the forecast period. Atopic dermatitis segment refers to a chronic, highly pruritic inflammatory skin disorder and is one of the most common skin diseases in children. In addition, it usually onsets in childhood and often gets milder or disappears by adulthood. Furthermore, even though it is a common type of atopic dermatitis and not contagious, it can be severe and long-lasting. Atopic dermatitis is found in around 10% of the worldwide population at some point in their life.

Get a glance at the market contribution of various segments Download PDF Sample

The atopic dermatitis segment was the largest segment and was valued at USD 5.13 billion in 2018. Moreover, this indication is usually more prevalent in developed countries and urban areas. In addition, atopic dermatitis in children may improve at times; however, it may worsen if triggered by certain allergens. Furthermore, although the indication may disappear as a child grows old, in some cases, it flares into adulthood. In addition, atopic dermatitis mostly has two allergic comorbidities, namely asthma and hay fever. Furthermore, people with either of these conditions or those who have a family history associated with these conditions are more likely to develop atopic dermatitis. Hence, such factors are fuelling the growth of this segment which in turn drives the market during the forecast period.

Distribution Channel Analysis

The hospitals and clinics segment, especially those with dermatology departments, are equipped to diagnose eczema through clinical evaluation, medical history assessment, and skin examinations. In addition, atopic dermatitis is often associated with comorbid conditions such as asthma, allergic rhinitis, and food allergies. Moreover, hospital pharmacies can supply medications to treat these comorbidities, as well as eczema-related complications such as skin infections, ensuring comprehensive care for patients with atopic dermatitis. Furthermore, dermatologists and healthcare providers in these settings have the expertise to differentiate atopic dermatitis from other skin conditions and determine appropriate treatment strategies. Hence, such factors are fuelling the growth of this segment which in turn drives the market during the forecast period.

The online pharmacies segment offers convenience and flexibility, allowing individuals to purchase eczema therapeutics from the comfort of their own homes. In addition, this convenience is particularly beneficial for patients with atopic dermatitis who may experience discomfort or mobility limitations that make it challenging to visit traditional brick-and-mortar pharmacies. Moreover, online pharmacies provide access to a wide range of eczema therapeutics, including prescription medications, over-the-counter products, and specialty skincare items. Individuals living in remote or rural areas with limited access to local pharmacies can conveniently order eczema treatments online and have them delivered to their doorstep. Hence, such factors are fuelling the growth of this segment which in turn drives the market during the forecast period.

Regional Analysis

For more insights about the market share of various regions Download PDF Sample now!

North America is estimated to contribute 42% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers will shape the market during the forecast period. The market growth in North America is influenced by factors such as early adoption of novel therapeutics, high awareness among the vastly susceptible cohort regarding the need for timely treatment, and the presence of established healthcare infrastructure in the region. In addition, the market is expected to demonstrate promising growth due to favorable reimbursement policies, growing partnerships of key companies with contract research organizations in emerging markets, and high healthcare expenditure.

Moreover, a large number of clinical trials are being conducted in the US, which evaluate promising product candidates for the treatment of various diseases, including atopic dermatitis. Furthermore, North America has one of the highest healthcare expenditures globally, with significant investments in healthcare services, pharmaceuticals, and medical research. Therefore, the willingness to spend on healthcare, coupled with insurance coverage and reimbursement policies, supports the adoption and utilization of atopic dermatitis therapeutics among patients in the region. Hence, such factors are driving the market in North America during the forecast period.

Buy Full Report Now

Key Market Players 

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:

AbbVie Inc: The company offers eczema therapeutics, namely Rinvoq, for adults and adolescents with moderate to severe atopic dermatitis.

Alliance Pharma PLC, Amneal Pharmaceuticals Inc., AstraZeneca PLC, Bausch Health Companies Inc., Bayer AG, Bristol-Myers Squibb Company, Cadila Pharmaceuticals Ltd., Eli Lilly and Co., Incyte Corp., LEO Pharma AS, Lupin Ltd., Mayo Clinic, Merck and Co. Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi SA, Teva Pharmaceutical Industries Ltd., and Viatris Inc.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Market Dynamics and Customer Landscape

The market is driven by a growing understanding of Genetics and the Immune system, leading to targeted treatments for Eczema, Dermatitis, and Atopic dermatitis. Advancements in Steroid creams, Topical steroids, and Antihistamines are aiding in managing Skin redness, Itchy skin, and Inflammation. Challenges include addressing Skin barrier dysfunction, providing effective Treatment for Dry, cracked, and itchy skin, and managing Inhalant and food allergens that exacerbate symptoms. Emerging trends focus on personalized therapies and innovative approaches to enhance Skin barrier repair and reduce Skin itching and Rashes. Our researchers analyzed the market research and growth data with 2023  as the base year, along with the key market growth analysis, trends, and challenges. A holistic analysis of drivers, trends, and challenges will help companies refine their marketing strategies to gain a competitive advantage. 

Key Market Drivers

The high prevalence of atopic dermatitis is notably driving the market. There is a high prevalence of eczema globally. Eczema can be caused owing to various factors, such as exposure to allergens such as peanuts, pollen, or pet dander, skin irritants including household cleaners, some fabrics, or soaps, stress, dry skin, and infections. In addition, atopic dermatitis is the most prevalent among all types of eczema, with around 18 million patients currently living in the US alone (according to the National Eczema Association (NEA)).

Moreover, in the US, around 9-10 million children aged under 18 years are estimated to have atopic dermatitis, of which around one-third have a moderate-to-severe form of the disease. In addition, such a large patient pool presents a significant opportunity for the growth of the global market. Furthermore, the large patient cohort requires multiple visits to dermatologists and numerous medications for the treatment of atopic dermatitis. Hence, such factors are driving the market during the forecast period.

Significant Market Trends

Increasing healthcare expenditure and surging demand for eczema therapeutics is an emerging trend in the market. With the rising prevalence of allergic and inflammatory skin diseases in people across the globe, healthcare expenditure is also increasing. In addition, for the treatment of highly prevalent diseases such as atopic dermatitis, dermatologists are prescribing a large number of OTC drugs and generic medications including corticosteroids, antihistamines, and topical antiseptics, due to the high number of clinical visits.

Moreover, the market is also witnessing an increased adoption of expensive, novel, and branded drugs for more effective treatment. In addition, the growing awareness of the need for early diagnosis of skin diseases, as well as the risks of negligence in seeking timely medical help, is making people increasingly health-conscious, which, in turn, is organically increasing healthcare expenditure. Hence, such factors are driving the market during the forecast period.

Major Market Challenges

Stringent regulatory guidelines for eczema therapeutics are a major challenge hindering the market. Several regulatory approval processes for this therapeutics, such as clinical trials, premarket submissions, and post-market surveillance, can be lengthy and resource-intensive. In addition, delays in obtaining regulatory approval may hinder the timely launch of new products and slow down market growth.

Moreover, one of the major hindrances to the approval of efficacious medications used in the treatment of atopic dermatitis is the failure of the drugs to meet the appropriate endpoints needed for a successful clinical trial. In addition, this has led to the failure of promising agents to receive regulatory approval in major Phase-II and Phase-III clinical studies. Furthermore, most clinical trials among several atopic dermatitis indications are focused on evaluating novel drugs for the treatment of atopic dermatitis. Hence, such factors are hindering the market during the forecast period.

Buy Now Full Report

Key Market Customer Landscape

The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

 Customer Landscape

Segment Overview

The market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2018 to 2028. 

• Application Outlook
  • Atopic dermatitis
  • Contact dermatitis
  • Other indication
• Distribution Channel Outlook
  • Hospital and clinics
  • Online pharmacies
  • Retail pharmacies
• Region Outlook
  • North America
    • The U.S.
    • Canada
  • Europe
    • The U.K.
    • Germany
    • France
    • Rest of Europe
  • Asia
    • China
    • India
  • Rest of the World (ROW)
    • Australia
    • Argentina
    • Brazil

Market Analyst Overview

Eczema, also known as atopic dermatitis, is a common skin condition characterized by rashes, skin redness, and itchy skin. The development of eczema is influenced by genetic factors and abnormalities in the immune system, affecting the skin barrier's integrity. Patients often experience dry, cracked, and itchy skin, leading to discomfort and irritation. Treatment for eczema involves a variety of therapeutic approaches. Steroid creams and ointments are commonly used to reduce inflammation and relieve symptoms such as itching and redness. Moisturizers play a crucial role in maintaining skin hydration and improving the skin barrier function. In cases of infection, antibiotics may be prescribed to address bacterial overgrowth and prevent complications.

Moreover, hand Thdermatitis, a specific form of eczema affecting the hands, requires targeted treatment approaches. Hand sanitizer and emollients help soothe skin irritation and protect against further damage. Topical steroids and ointments are applied to manage inflammation and promote healing. Recent advancements in eczema therapeutics include the introduction of PDE4 inhibitors, immunomodulators, and interleukin inhibitors. These medications target abnormal immune system function and alleviate eczema symptoms effectively. Emollients and probiotics are also utilized to support skin health and manage eczema-related discomfort.

Furthermore, the market encompasses a wide array of treatments and interventions aimed at managing the symptoms and underlying causes of atopic eczema. One of the key factors influencing eczema is genetics, as individuals with a family history of eczema are more likely to develop the condition. Environmental triggers such as inhalants and food allergens can exacerbate eczema symptoms, leading to skin itching and irritation. Various medical therapies are available to address eczema, ranging from steroid medicines and injectable treatments to innovative solutions like whipped foam eczema relief therapy delivered through a foam delivery system. These therapies target inflammation, reduce itching, and restore the skin barrier function, providing relief to patients with atopic eczema.

In addition, the use of hand sanitizers is important for eczema patients to maintain hand hygiene without aggravating their skin condition. Research into emerging treatments, such as the use of Roseomonas mucosa bacteria, shows promise in modulating the immune response and improving eczema outcomes. In the market, advancements in drug formulations in drug class and delivery systems, such as the development of injectable medications and novel foam-based therapies, are enhancing treatment efficacy and patient convenience. Understanding the role of genes and genetic factors in eczema susceptibility is also driving personalized treatment approaches tailored to individual patient needs.

Market Scope
Report Coverage	Details
Page number	172
Base year	2023
Historic period	2018-2022
Forecast period	2024-2028
Growth momentum & CAGR	Accelerate at a CAGR of 10.28%
Market Growth 2024-2028	USD 5.81 billion
Market structure	Fragmented
YoY growth 2023-2024(%)	9.55
Regional analysis	North America, Europe, Asia, and the Rest of the World (ROW)
Performing market contribution	North America at 42%
Key countries	US, Canada, Germany, UK, and China
Competitive landscape	Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks
Key companies profiled	AbbVie Inc., Alliance Pharma PLC, Amneal Pharmaceuticals Inc., AstraZeneca PLC, Bausch Health Companies Inc., Bayer AG, Bristol-Myers Squibb Company, Cadila Pharmaceuticals Ltd., Eli Lilly and Co., Incyte Corp., LEO Pharma AS, Lupin Ltd., Mayo Clinic, Merck and Co. Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi SA, Teva Pharmaceutical Industries Ltd., and Viatris Inc.
Market dynamics	Parent market analysis, Market forecasting, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period.
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Download Sample PDF at your Fingertips

What are the Key Data Covered in this Market Research Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the growth of the between 2024 and 2028
• Precise estimation of the size of the size and its contribution to the market in focus on the parent market
• Detailed analysis of customer landscape covering Diver of price sensitivity, Adoption of the lifecycle, and key purchase criteria 
• Companies landscape comparing criticality of inputs and factors of differentiation
• Exclusive Matrix on companies position and classification
• Accurate predictions about upcoming trends and changes in consumer behavior
• Growth of the market across North America, Europe, Asia, and Rest of World (ROW)
• Thorough market growth and forecasting analysis of the market’s competitive landscape and detailed information about companies
• Comprehensive analysis of factors that will challenge the growth of companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch